Tendon & Ligament
Achilles tendon, MCL and rotator cuff models in rats, with collagen fibre organisation among the measured endpoints.
≥99% Purity
BPC-157
Pentadecapeptide · Preclinical Models
$60.00$30.00/vial with BOGO
USA Lab VerifiedISO/IEC 17025:2017
QuantityBuy 1 Get 1 Free · auto-appliedAdd 2+ items to cart to activate the discount
Free Shipping on orders over $200
PASSEDSterility & Endotoxins
PASSEDNet Content & Purity
Researchers also added
Authenticity
Every vial is QR-authenticated
Scan the QR code on any vial to verify its batch, COA, and origin in seconds. Secure traceability from our lab to your bench.
About this compound
BPC-157 is a synthetic peptide, 15 amino acids long. It copies part of a larger protein found in human stomach fluid. Research in animal models has measured new blood vessel growth, how tendon cells move and spread, and how tissue remodels after injury. It holds up in stomach acid better than most peptides, which is unusual and has been studied on its own.
Synthetic pentadecapeptide (15 amino acids)
- Formula
- C62H98N16O22
- Molecular weight
- 1419.53 g/mol
- Form
- Lyophilized powder
- CAS / ID
- 137525-51-0
0
Amino Acid Sequence
Synthetic pentadecapeptide
0×
GHR Upregulation
Tendon fibroblasts by day 3
0
Research Areas
Tendon & Ligament · Gastrointestinal · Neural & more
How It Works
How BPC-157 works
The pathways BPC-157 acts on — and what each one does. The animation traces its signal outward from the compound to every target it engages.
Signalling pathways studied in preclinical models · illustrative
VEGF & Angiogenic Signalling
VEGF Pathway
In preclinical models, raised vascular endothelial growth factor (VEGF) expression has been measured following BPC-157 exposure, with vessel formation and perfusion recorded in the same models.
- Vessel formation measured in animal models (angiogenesis)
- Raised VEGF receptor expression reported
- Modulates nitric oxide signaling (NO system)
GHR Upregulation
Growth Hormone
Growth hormone receptor expression in cultured tendon fibroblasts has been measured at approximately 7× baseline within 3 days of exposure.
- 7× growth hormone receptor upregulation
- Tendon fibroblast viability measured in culture
- Collagen synthesis signalling examined
Cytoprotective Signalling
Cytoprotective
Cytoprotective endpoints have been examined across several organ systems in animal studies, most often in gastrointestinal and musculoskeletal tissue.
- Gastric mucosal integrity endpoints
- Faster wound closure recorded in animal models
- Neuroprotective endpoints observed in rodent models
Uses & Applications
What BPC-157 is researched for
The main areas BPC-157 is being studied for — and the study-reported figures behind them.
Gastrointestinal Models
Cytoprotective endpoints examined in NSAID-induced injury, alcohol lesion and colitis models.
Brain & Nervous System
Neuroprotective endpoints examined in traumatic brain injury and peripheral nerve models, including functional markers.
Vascular Models
Studied for angiogenesis after surgical transection in animal models, via NO system modulation.
Molecular Structure
The BPC-157 molecule
An interactive 3D model rendered from the compound record — rotate and explore its structure.
C62H98N16O22
Compound Information
Full specification
| Sequence | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
| Molecular Weight | 1419.53 Da |
| Molecular Formula | C₆₂H₉₈N₁₆O₂₂ |
| Form | Lyophilized powder (5mg) |
| Purity | ≥99% (HPLC verified) |
| Testing | Third-party HPLC, Mass Spec, Endotoxin |
| Storage | -20°C for long-term stability |
| Solubility | Water-soluble |
| COA | Included with every order |
FAQ
Common questions about BPC-157
BPC-157 (Body Protection Compound-157) is a synthetic 15-amino acid peptide derived from a larger protein found in human gastric juice. It was first characterised at the University of Zagreb, Croatia, and has been studied extensively in animal models across cytoprotective and tissue-remodelling endpoints.
No. BPC-157 is not approved by the FDA or any regulatory agency for human use. It is classified as an unapproved drug. The FDA has issued warnings about BPC-157 being found in compounded products and dietary supplements. Only one Phase I clinical trial has been registered, and no Phase 2 or 3 trials have been completed.
Preclinical research (animal studies) has reported BPC-157 in tendon, ligament, muscle and bone models; in gastrointestinal lesion and inflammation models; in neuroprotection models of brain injury; and in blood-vessel formation. All findings are from animal studies - no human clinical data exists.
BPC-157 has been studied in rodent models and in cultured cell systems, with tissue-remodelling and gastrointestinal endpoints. Study design, concentrations and endpoints differ between experiments.
No lethal dose was reached in preclinical toxicology studies, and no significant adverse effects have been reported in published research. However, BPC-157 has never completed human clinical trials, so its safety profile in humans is unknown. It should only be used for in vitro laboratory research.
Lyophilized (powder) form should be stored at -20°C for long-term stability, protected from light and moisture. BPC-157 is notably stable — it resists hydrolysis, enzymatic degradation, and gastric acid.
Research Use Only.
Not for human or veterinary use. For in-vitro laboratory research only. These statements have not been evaluated by the FDA; this product is not intended to diagnose, treat, cure, or prevent any disease. Sold exclusively to qualified researchers and institutions.